Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 93

1.

Anthracycline-induced clinical heart failure in a cohort of 607 children: long-term follow-up study.

Kremer LC, van Dalen EC, Offringa M, Ottenkamp J, Voûte PA.

J Clin Oncol. 2001 Jan 1;19(1):191-6.

PMID:
11134212
2.

Clinical heart failure in a cohort of children treated with anthracyclines: a long-term follow-up study.

van Dalen EC, van der Pal HJ, Kok WE, Caron HN, Kremer LC.

Eur J Cancer. 2006 Dec;42(18):3191-8. Epub 2006 Sep 20.

PMID:
16987655
3.

Clinical heart failure during pregnancy and delivery in a cohort of female childhood cancer survivors treated with anthracyclines.

van Dalen EC, van der Pal HJ, van den Bos C, Kok WE, Caron HN, Kremer LC.

Eur J Cancer. 2006 Oct;42(15):2549-53. Epub 2006 Aug 17.

PMID:
16919450
4.

Congestive heart failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer.

Pinder MC, Duan Z, Goodwin JS, Hortobagyi GN, Giordano SH.

J Clin Oncol. 2007 Sep 1;25(25):3808-15. Epub 2007 Jul 30.

PMID:
17664460
5.

High risk of symptomatic cardiac events in childhood cancer survivors.

van der Pal HJ, van Dalen EC, van Delden E, van Dijk IW, Kok WE, Geskus RB, Sieswerda E, Oldenburger F, Koning CC, van Leeuwen FE, Caron HN, Kremer LC.

J Clin Oncol. 2012 May 1;30(13):1429-37. doi: 10.1200/JCO.2010.33.4730. Epub 2012 Apr 2.

PMID:
22473161
6.

Clinical cardiotoxicity following anthracycline treatment for childhood cancer: the Pediatric Oncology Group experience.

Krischer JP, Epstein S, Cuthbertson DD, Goorin AM, Epstein ML, Lipshultz SE.

J Clin Oncol. 1997 Apr;15(4):1544-52.

PMID:
9193351
7.

Equivalence Ratio for Daunorubicin to Doxorubicin in Relation to Late Heart Failure in Survivors of Childhood Cancer.

Feijen EA, Leisenring WM, Stratton KL, Ness KK, van der Pal HJ, Caron HN, Armstrong GT, Green DM, Hudson MM, Oeffinger KC, Robison LL, Stovall M, Kremer LC, Chow EJ.

J Clin Oncol. 2015 Nov 10;33(32):3774-80. doi: 10.1200/JCO.2015.61.5187. Epub 2015 Aug 24.

8.

Cardiac toxicity after anthracycline chemotherapy in childhood.

Iarussi D, Indolfi P, Galderisi M, Bossone E.

Herz. 2000 Nov;25(7):676-88. Review.

PMID:
11141677
9.

Anthracycline-related cardiomyopathy after childhood cancer: role of polymorphisms in carbonyl reductase genes--a report from the Children's Oncology Group.

Blanco JG, Sun CL, Landier W, Chen L, Esparza-Duran D, Leisenring W, Mays A, Friedman DL, Ginsberg JP, Hudson MM, Neglia JP, Oeffinger KC, Ritchey AK, Villaluna D, Relling MV, Bhatia S.

J Clin Oncol. 2012 May 1;30(13):1415-21. doi: 10.1200/JCO.2011.34.8987. Epub 2011 Nov 28.

10.

Frequency and risk factors of anthracycline-induced clinical heart failure in children: a systematic review.

Kremer LC, van Dalen EC, Offringa M, Voûte PA.

Ann Oncol. 2002 Apr;13(4):503-12. Review.

PMID:
12056699
11.

Cardiac function in Wilms' tumor survivors.

Sorensen K, Levitt G, Sebag-Montefiore D, Bull C, Sullivan I.

J Clin Oncol. 1995 Jul;13(7):1546-56.

PMID:
7602343
12.

Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy.

Cardinale D, Colombo A, Bacchiani G, Tedeschi I, Meroni CA, Veglia F, Civelli M, Lamantia G, Colombo N, Curigliano G, Fiorentini C, Cipolla CM.

Circulation. 2015 Jun 2;131(22):1981-8. doi: 10.1161/CIRCULATIONAHA.114.013777. Epub 2015 May 6.

13.

Cardioprotective effect of dexrazoxane in patients with breast cancer treated with anthracyclines in adjuvant setting: a 10-year single institution experience.

Testore F, Milanese S, Ceste M, de Conciliis E, Parello G, Lanfranco C, Manfredi R, Ferrero G, Simoni C, Miglietta L, Ferro S, Giaretto L, Bosso G.

Am J Cardiovasc Drugs. 2008;8(4):257-63.

PMID:
18690759
14.

Late cardiotoxicity after low dose of anthracycline therapy for acute lymphoblastic leukemia in childhood.

Vandecruys E, Mondelaers V, De Wolf D, Benoit Y, Suys B.

J Cancer Surviv. 2012 Mar;6(1):95-101. doi: 10.1007/s11764-011-0186-6. Epub 2011 Jun 1.

15.

Medical interventions for treating anthracycline-induced symptomatic and asymptomatic cardiotoxicity during and after treatment for childhood cancer.

Cheuk DK, Sieswerda E, van Dalen EC, Postma A, Kremer LC.

Cochrane Database Syst Rev. 2016 Aug 23;(8):CD008011. doi: 10.1002/14651858.CD008011.pub3. Review.

PMID:
27552363
16.
17.

Exercise echocardiography in asymptomatic survivors of childhood cancer treated with anthracyclines: a prospective follow-up study.

Sieswerda E, Kremer LC, Vidmar S, De Bruin ML, Smibert E, Sjöberg G, Cheung MM, Weintraub RG.

Pediatr Blood Cancer. 2010 Apr;54(4):579-84. doi: 10.1002/pbc.22371.

PMID:
20014238
18.

Cardiac toxicity 4 to 20 years after completing anthracycline therapy.

Steinherz LJ, Steinherz PG, Tan CT, Heller G, Murphy ML.

JAMA. 1991 Sep 25;266(12):1672-7.

PMID:
1886191
19.

Genetic polymorphisms in the carbonyl reductase 3 gene CBR3 and the NAD(P)H:quinone oxidoreductase 1 gene NQO1 in patients who developed anthracycline-related congestive heart failure after childhood cancer.

Blanco JG, Leisenring WM, Gonzalez-Covarrubias VM, Kawashima TI, Davies SM, Relling MV, Robison LL, Sklar CA, Stovall M, Bhatia S.

Cancer. 2008 Jun 15;112(12):2789-95. doi: 10.1002/cncr.23534.

20.

Anthracycline-induced heart failure.

van Dalen EC.

Nat Clin Pract Oncol. 2007 Dec;4(12):E1. No abstract available.

PMID:
18037871

Supplemental Content

Support Center